Overview

A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc